Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Teva Pharmaceutical Industries Ltd.
Nieuws
Teva Ltd.
TEVA
NYS
: TEVA
| ISIN: US8816242098
20/11/2026
39,23 USD
(+1,79%)
(+1,79%)
20/11/2026
Aandeel volgen
Aandeel gevolgd
Samenvatting
Adviezen
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
20 november 2026 ·
Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference
· Persbericht
20 november 2026 ·
Teva Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Teva (TEVA)
· Persbericht
18 november 2026 ·
Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company
· Persbericht
16 november 2026 ·
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
· Persbericht
11 november 2026 ·
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
· Persbericht
3 november 2026 ·
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
· Persbericht
3 november 2026 ·
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
· Persbericht
2 november 2026 ·
Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis
· Persbericht
27 oktober 2026 ·
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
· Persbericht
20 oktober 2026 ·
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
· Persbericht
12 oktober 2026 ·
Teva to Host R&D Day on Wednesday, November 11 in New York City
· Persbericht
9 oktober 2026 ·
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
· Persbericht
2 oktober 2026 ·
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
· Persbericht
2 oktober 2026 ·
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
· Persbericht
30 september 2026 ·
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
· Persbericht
28 september 2026 ·
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
· Persbericht
23 september 2026 ·
Teva Releases Q3 2026 Aide Memoire
· Persbericht
23 september 2026 ·
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
· Persbericht
18 september 2026 ·
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
· Persbericht
18 september 2026 ·
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe